Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000531811 | SCV000635483 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2024-05-19 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 1980 of the BRCA2 protein (p.Thr1980Pro). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 462394). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on BRCA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000568300 | SCV000666126 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-10-18 | criteria provided, single submitter | clinical testing | The p.T1980P variant (also known as c.5938A>C), located in coding exon 10 of the BRCA2 gene, results from an A to C substitution at nucleotide position 5938. The threonine at codon 1980 is replaced by proline, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV000568300 | SCV000911764 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-04-18 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with proline at codon 1980 of the BRCA2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_007408). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
University of Washington Department of Laboratory Medicine, |
RCV000568300 | SCV003850800 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Genetics and Molecular Pathology, |
RCV003447541 | SCV004175366 | uncertain significance | Fanconi anemia complementation group D1 | 2023-01-12 | criteria provided, single submitter | clinical testing | The BRCA2 c.5938A>C variant is classified as VUS (PM2, PP3) The BRCA2 c.5938A>C variant is a single nucleotide change in exon 11/27 of the BRCA2 gene, which is predicted to change the amino acid threonine at position 1980 in the protein to proline. This variant is absent from population databases (PM2). This variant has been reported in an individual affected with breast cancer (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_007408) Computational predictions support a deleterious effect on the gene or gene product (PP3). The variant has been reported in dbSNP (rs55877890) and has been reported as Uncertain significance by other diagnostic laboratories (ClinVar Variation ID: 462394). It has not been reported in HGMD. |
All of Us Research Program, |
RCV003999064 | SCV004846674 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-05-04 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with proline at codon 1980 of the BRCA2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA2_007408). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |